---
document_datetime: 2025-11-23 08:04:59
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/zoledronic-acid-teva-pharma.html
document_name: zoledronic-acid-teva-pharma.html
version: success
processing_time: 0.1071807
conversion_datetime: 2025-12-25 10:11:33.61984
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Zoledronic acid Teva Pharma

[RSS](/en/individual-human-medicine.xml/66163)

##### Withdrawn

This medicine's authorisation has been withdrawn

zoledronic acid

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 18 January 2018 the European Commission withdrew the marketing authorisation for Zoledronic acid Teva Pharma (zoledronic acid) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Teva B.V., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Zoledronic acid Teva Pharma was granted marketing authorisation in the EU on 16 August 2012 for treatment of osteoporosis. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2017.

Zoledronic acid Teva Pharma is a generic medicine of Aclasta. There are other generic medicines of Aclasta authorised and marketed in the EU.

The European public assessment report (EPAR) for Zoledronic acid Teva Pharma is updated to reflect the fact that the marketing authorisation is no longer valid.

Zoledronic acid Teva Pharma : EPAR - Summary for the public

Reference Number: EMA/227536/2012

English (EN) (545.49 KB - PDF)

**First published:** 28/08/2012

**Last updated:** 12/12/2018

[View](/en/documents/overview/zoledronic-acid-teva-pharma-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-168)

български (BG) (632.92 KB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/bg/documents/overview/zoledronic-acid-teva-pharma-epar-summary-public_bg.pdf)

español (ES) (547.09 KB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/es/documents/overview/zoledronic-acid-teva-pharma-epar-summary-public_es.pdf)

čeština (CS) (610.25 KB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/cs/documents/overview/zoledronic-acid-teva-pharma-epar-summary-public_cs.pdf)

dansk (DA) (545.29 KB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/da/documents/overview/zoledronic-acid-teva-pharma-epar-summary-public_da.pdf)

Deutsch (DE) (547.85 KB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/de/documents/overview/zoledronic-acid-teva-pharma-epar-summary-public_de.pdf)

eesti keel (ET) (543.32 KB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/et/documents/overview/zoledronic-acid-teva-pharma-epar-summary-public_et.pdf)

ελληνικά (EL) (638.97 KB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/el/documents/overview/zoledronic-acid-teva-pharma-epar-summary-public_el.pdf)

français (FR) (548.22 KB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/fr/documents/overview/zoledronic-acid-teva-pharma-epar-summary-public_fr.pdf)

hrvatski (HR) (561.29 KB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/hr/documents/overview/zoledronic-acid-teva-pharma-epar-summary-public_hr.pdf)

italiano (IT) (544.72 KB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/it/documents/overview/zoledronic-acid-teva-pharma-epar-summary-public_it.pdf)

latviešu valoda (LV) (607.99 KB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/lv/documents/overview/zoledronic-acid-teva-pharma-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (572.59 KB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/lt/documents/overview/zoledronic-acid-teva-pharma-epar-summary-public_lt.pdf)

magyar (HU) (605.69 KB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/hu/documents/overview/zoledronic-acid-teva-pharma-epar-summary-public_hu.pdf)

Malti (MT) (614.17 KB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/mt/documents/overview/zoledronic-acid-teva-pharma-epar-summary-public_mt.pdf)

Nederlands (NL) (547.75 KB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/nl/documents/overview/zoledronic-acid-teva-pharma-epar-summary-public_nl.pdf)

polski (PL) (609.66 KB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/pl/documents/overview/zoledronic-acid-teva-pharma-epar-summary-public_pl.pdf)

português (PT) (547.55 KB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/pt/documents/overview/zoledronic-acid-teva-pharma-epar-summary-public_pt.pdf)

română (RO) (571.4 KB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/ro/documents/overview/zoledronic-acid-teva-pharma-epar-summary-public_ro.pdf)

slovenčina (SK) (611.08 KB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/sk/documents/overview/zoledronic-acid-teva-pharma-epar-summary-public_sk.pdf)

slovenščina (SL) (596.06 KB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/sl/documents/overview/zoledronic-acid-teva-pharma-epar-summary-public_sl.pdf)

Suomi (FI) (543.95 KB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/fi/documents/overview/zoledronic-acid-teva-pharma-epar-summary-public_fi.pdf)

svenska (SV) (538.99 KB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/sv/documents/overview/zoledronic-acid-teva-pharma-epar-summary-public_sv.pdf)

## Product information

Zoledronic acid Teva Pharma : EPAR - Product Information

English (EN) (1.07 MB - PDF)

**First published:** 28/08/2012

**Last updated:** 12/12/2018

[View](/en/documents/product-information/zoledronic-acid-teva-pharma-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-582)

български (BG) (2.48 MB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/bg/documents/product-information/zoledronic-acid-teva-pharma-epar-product-information_bg.pdf)

español (ES) (1.16 MB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/es/documents/product-information/zoledronic-acid-teva-pharma-epar-product-information_es.pdf)

čeština (CS) (2.01 MB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/cs/documents/product-information/zoledronic-acid-teva-pharma-epar-product-information_cs.pdf)

dansk (DA) (1.06 MB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/da/documents/product-information/zoledronic-acid-teva-pharma-epar-product-information_da.pdf)

Deutsch (DE) (1.13 MB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/de/documents/product-information/zoledronic-acid-teva-pharma-epar-product-information_de.pdf)

eesti keel (ET) (1.13 MB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/et/documents/product-information/zoledronic-acid-teva-pharma-epar-product-information_et.pdf)

ελληνικά (EL) (2.6 MB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/el/documents/product-information/zoledronic-acid-teva-pharma-epar-product-information_el.pdf)

français (FR) (1.21 MB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/fr/documents/product-information/zoledronic-acid-teva-pharma-epar-product-information_fr.pdf)

hrvatski (HR) (1.12 MB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/hr/documents/product-information/zoledronic-acid-teva-pharma-epar-product-information_hr.pdf)

íslenska (IS) (1.15 MB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/is/documents/product-information/zoledronic-acid-teva-pharma-epar-product-information_is.pdf)

italiano (IT) (1.1 MB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/it/documents/product-information/zoledronic-acid-teva-pharma-epar-product-information_it.pdf)

latviešu valoda (LV) (2.07 MB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/lv/documents/product-information/zoledronic-acid-teva-pharma-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.23 MB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/lt/documents/product-information/zoledronic-acid-teva-pharma-epar-product-information_lt.pdf)

magyar (HU) (2.03 MB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/hu/documents/product-information/zoledronic-acid-teva-pharma-epar-product-information_hu.pdf)

Malti (MT) (2.02 MB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/mt/documents/product-information/zoledronic-acid-teva-pharma-epar-product-information_mt.pdf)

Nederlands (NL) (1.1 MB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/nl/documents/product-information/zoledronic-acid-teva-pharma-epar-product-information_nl.pdf)

norsk (NO) (1.14 MB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/no/documents/product-information/zoledronic-acid-teva-pharma-epar-product-information_no.pdf)

polski (PL) (2.42 MB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/pl/documents/product-information/zoledronic-acid-teva-pharma-epar-product-information_pl.pdf)

português (PT) (1.07 MB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/pt/documents/product-information/zoledronic-acid-teva-pharma-epar-product-information_pt.pdf)

română (RO) (1.15 MB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/ro/documents/product-information/zoledronic-acid-teva-pharma-epar-product-information_ro.pdf)

slovenčina (SK) (2.05 MB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/sk/documents/product-information/zoledronic-acid-teva-pharma-epar-product-information_sk.pdf)

slovenščina (SL) (1.95 MB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/sl/documents/product-information/zoledronic-acid-teva-pharma-epar-product-information_sl.pdf)

Suomi (FI) (1.1 MB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/fi/documents/product-information/zoledronic-acid-teva-pharma-epar-product-information_fi.pdf)

svenska (SV) (1.08 MB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/sv/documents/product-information/zoledronic-acid-teva-pharma-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** R/0014 18/01/2018

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Zoledronic acid Teva Pharma : EPAR - Conditions imposed on member states for safe and effective use

English (EN) (486.12 KB - PDF)

**First published:** 28/08/2012

**Last updated:** 12/12/2018

[View](/en/documents/conditions-member-states/zoledronic-acid-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_en.pdf)

[Other languages (23)](#file-language-dropdown-620)

български (BG) (568.81 KB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/bg/documents/conditions-member-states/zoledronic-acid-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_bg.pdf)

español (ES) (487.29 KB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/es/documents/conditions-member-states/zoledronic-acid-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_es.pdf)

čeština (CS) (543.68 KB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/cs/documents/conditions-member-states/zoledronic-acid-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_cs.pdf)

dansk (DA) (485.83 KB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/da/documents/conditions-member-states/zoledronic-acid-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_da.pdf)

Deutsch (DE) (486.57 KB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/de/documents/conditions-member-states/zoledronic-acid-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_de.pdf)

eesti keel (ET) (486.94 KB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/et/documents/conditions-member-states/zoledronic-acid-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_et.pdf)

ελληνικά (EL) (564.87 KB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/el/documents/conditions-member-states/zoledronic-acid-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_el.pdf)

français (FR) (487.32 KB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/fr/documents/conditions-member-states/zoledronic-acid-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_fr.pdf)

íslenska (IS) (495.52 KB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/is/documents/conditions-member-states/zoledronic-acid-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_is.pdf)

italiano (IT) (491.8 KB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/it/documents/conditions-member-states/zoledronic-acid-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_it.pdf)

latviešu valoda (LV) (555.98 KB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/lv/documents/conditions-member-states/zoledronic-acid-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_lv.pdf)

lietuvių kalba (LT) (520.72 KB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/lt/documents/conditions-member-states/zoledronic-acid-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_lt.pdf)

magyar (HU) (543.33 KB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/hu/documents/conditions-member-states/zoledronic-acid-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_hu.pdf)

Malti (MT) (542.43 KB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/mt/documents/conditions-member-states/zoledronic-acid-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_mt.pdf)

Nederlands (NL) (486.71 KB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/nl/documents/conditions-member-states/zoledronic-acid-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_nl.pdf)

norsk (NO) (490.89 KB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/no/documents/conditions-member-states/zoledronic-acid-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_no.pdf)

polski (PL) (545.07 KB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/pl/documents/conditions-member-states/zoledronic-acid-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_pl.pdf)

português (PT) (493.8 KB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/pt/documents/conditions-member-states/zoledronic-acid-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_pt.pdf)

română (RO) (527.31 KB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/ro/documents/conditions-member-states/zoledronic-acid-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_ro.pdf)

slovenčina (SK) (504.76 KB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/sk/documents/conditions-member-states/zoledronic-acid-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_sk.pdf)

slovenščina (SL) (537.91 KB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/sl/documents/conditions-member-states/zoledronic-acid-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_sl.pdf)

Suomi (FI) (490.79 KB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/fi/documents/conditions-member-states/zoledronic-acid-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_fi.pdf)

svenska (SV) (487.54 KB - PDF)

**First published:**

28/08/2012

**Last updated:**

12/12/2018

[View](/sv/documents/conditions-member-states/zoledronic-acid-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_sv.pdf)

## Product details

Name of medicine Zoledronic acid Teva Pharma Active substance zoledronic acid International non-proprietary name (INN) or common name zoledronic acid Therapeutic area (MeSH)

- Osteoporosis
- Osteitis Deformans
- Osteoporosis, Postmenopausal

Anatomical therapeutic chemical (ATC) code M05BA08

### Pharmacotherapeutic group

Drugs for treatment of bone diseases

### Therapeutic indication

Treatment of osteoporosis:

- in post-menopausal women;
- in men;

at increased risk of fracture including those with a recent low-trauma hip fracture.

Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy:

- in post-menopausal women;
- in men;

at increased risk of fracture.

Treatment of Paget's disease of the bone in adults.

## Authorisation details

EMA product number EMEA/H/C/002437

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Teva B.V.

Swensweg 5

Marketing authorisation issued 15/08/2012 Withdrawal of marketing authorisation 18/01/2018 Revision 11

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Zoledronic acid Teva Pharma : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (568.74 KB - PDF)

**First published:** 20/08/2013

**Last updated:** 12/12/2018

[View](/en/documents/procedural-steps-after/zoledronic-acid-teva-pharma-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Zoledronic acid Teva Pharma : EPAR - Public assessment report

Reference Number: EMA/534119/2012

English (EN) (714.34 KB - PDF)

**First published:** 28/08/2012

**Last updated:** 12/12/2018

[View](/en/documents/assessment-report/zoledronic-acid-teva-pharma-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Zoledronic acid Teva Pharma

Adopted

Reference Number: EMA/176371/2012

English (EN) (520.29 KB - PDF)

**First published:** 16/03/2012

**Last updated:** 12/12/2018

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-zoledronic-acid-teva-pharma_en.pdf)

**This page was last updated on** 12/12/2018

## Share this page

[Back to top](#main-content)